A Phase 3 interventional study of Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII and Placebo in Von Willebrand Diseases, sponsored by Unity Health Toronto. Recruiting at 2 sites in Canada. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by Unity Health Toronto · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and to explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial
The EMPOWER trial is a pilot multi-center, placebo-controlled (normal saline), double-blind (patient and outcome assessor), crossover, 2-year randomized trial in female outpatients with von Willebrand disease (VWD) and heavy menstrual bleeding to determine trial feasibility and viability, and explore assay sensitivity of the proposed efficacy clinical outcomes for a definitive randomized controlled trial.
For the first treatment period, patients will be randomized to receive either plasma derived von Willebrand factor:Factor VIII (pdVWF:FVIII) concentrate (plus standard of care) or placebo (plus standard of care) for VWD-associated heavy menstrual bleeding for 4 cycles, crossing over to the comparator treatment during the second treatment period. The first treatment period will be followed by a 1 cycle washout period when no study-based treatment will be delivered.
The main purpose of the pilot will be to evaluate viability and feasibility of the trial design, as well as to explore assay sensitivity to inform determination of the primary efficacy outcome for the definitive randomized trial which will evaluate the effect of prophylaxis with pdVWF:FVIII concentrate compared with placebo on HMB in women with VWD. A secondary objective is to conduct a preliminary assessment of the effect on clinical outcomes of 2-3 doses of prophylaxis with pdVWF:FVIII concentrate when provided on the first 4 days of menstruation compared with placebo.
96 studies on the registry are indexed under von Willebrand Diseases; 25 are open to participants now.
This study's planned enrollment of 20 is below the median of 25 across 41 interventional studies indexed under von Willebrand Diseases.
Browse von Willebrand Diseases studies →Unity Health Toronto is the lead sponsor of 447 studies on the registry; 81 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 1 (20%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Wilate® at a dose of 30-60 IU VWF:RCo/kg for the two anticipated heaviest days of bleeding every 24-48 hours within the first 4 days of menstruation will be provided. Additional two optional doses 24-48 hours from the last can be provided. A minimum of 2 doses must be provided.
Drug: Lyophilized concentrate of human coagulation von Willebrand Factor and factor VIII
Patients randomized to the placebo arm will receive intravenous placebo (normal saline) at the same approximate volume and frequency as the study drug.
Other: Placebo
Wilate® is a plasma-derived, highly purified concentrate administered through intravenous injection. Wilate® contains an average VWF ristocetin cofactor activity to FVIII activity at ratio of 1:1.
Also known as: Wilate
Patients randomized to the placebo arm will receive intravenous normal saline at the same approximate volume and frequency of Wilate ®.
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2
Blinding Index (BI) score at the end of cycle 4 of treatment period 1 and 2
Time frame: 2 years
Proportion of participant drop-out at the end of treatment period 1 and 2
Proportion of participant drop-out at the end of treatment period 1 and 2
Time frame: 2 years
Proportion of participants with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2
Proportion of patients with completed for the candidate primary clinical efficacy outcomes at the end of treatment period 1 and 2
Time frame: 2 years
Number of participants enrolled in 2 years (i.e. ability to enroll at least 10 participants in 2 years)
Ability to enroll at least 10 participants in 2 years
Time frame: 2 years
Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2
Proportion of participants with carryover effect for the candidate primary clinical efficacy outcomes from period 1 to period 2
Time frame: 2 years
Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period
Mean of the 3 highest daily Modified PBAC (mPBAC) scores within each individual participant cycle averaged across 4 individual participant cycles at the end of each treatment period
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
The proportion of patients who use of rescue therapy at the end of each treatment period
The proportion of patients who use of rescue therapy (i.e. more than two days of oral tranexamic acid use, additional treatment with Wilate®, additional hormonal therapy for HMB, urgent/emergent gynecological surgery for HMB, treatment with intravenous iron, red blood cell transfusion, or hospital admission for HMB) at the end of each treatment period
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles
Mean of the mPBAC score within each individual participant cycle averaged across 4 individual participant cycles
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles
Median of the mPBAC score within each individual participant cycle used to derive the median across 4 individual participant cycles
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of days of oral tranexamic acid use
Number of days of oral tranexamic acid use
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of days of Wilate® treatment received
Number of days of Wilate® treatment received
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Duration of menstruation (measured in days)
Duration of menstruation (measured in days)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition
Major bleed according to the International Society on Thrombosis and Haemostasis (ISTH) definition
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Clinically relevant non-major bleed
Clinically relevant non-major bleed
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Hemoglobin levels (g/L)
Hemoglobin levels (g/L)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Ferritin levels (mcg/L)
Ferritin levels (mcg/L)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Use of additional hormonal therapy for heavy menstrual bleeding
Use of additional hormonal therapy for heavy menstrual bleeding
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding
Requirement of urgent/emergent gynecological surgery for heavy menstrual bleeding
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Fatigue scores (as measured by the FACIT fatigue scale)
Fatigue scores (as measured by the FACIT fatigue scale)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Short Form-12 Scores
Short Form-12 Scores
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Scores on the individual components of the Short Form-12
Scores on the individual components of the Short Form-12
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)
Requirement of hemostatic care (tranexamic acid, Wilate®, platelet transfusion)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)
Requirement of anemia focused care (intravenous iron and/or red blood cell transfusion)
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of hypersensitivity infusion reactions
Number of hypersensitivity infusion reactions
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
Number of thromboembolic events (defined as symptomatic or incidental, suspected or confirmed via diagnostic imaging and/or electrocardiogram where appropriate);
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Proportion of participants who development of VWF inhibitors
Proportion of participants who development of VWF inhibitors
Time frame: At the end of 8 menstrual cycles (approximately 10 days)
Number of adverse events
Number of adverse events
Time frame: 8 cycles
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2024 (actual). Primary completion is estimated for Dec 2027, 38 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Sep 2026 → Dec 2027 and completion Sep 2026 → Sep 2028.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.